NEW YORK (GenomeWeb News) – Genomics services firm BioServe will use biosamples from Philadelphia's Fox Chase Cancer Center to supplement its Global Repository under an exclusive two-year agreement, the Beltsville, Md.-based company said.

The agreement is part of an effort to plug up a "shortage of clinical quality biomaterials" for use in genetic and biomarker-focused cancer research that has caused a bottleneck in biotechnology research, BioServe said.